PremiumRatingsAgios Pharma: Promising Growth with Strategic Market Expansion and Pipeline Advancements Agios Pharmaceuticals reports Q4 revenue $10.7M, consensus $9.35M Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study PremiumThe FlyAgios Pharmaceuticals announces key 2025 milestones, catalysts through 2026 Agios Pharmaceuticals announces FDA accepted sNDA for PYRUKYND Agios Pharmaceuticals price target lowered to $55 from $60 at BofA PremiumThe FlyAgios presents results from Phase 3 ENERGIZE-T Study of Mitapivat Agios Pharmaceuticals to present new data on mitapivat, tebapivat Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank